Our Mission
Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections.
Tebipenem HBr
An investigational oral carbapenem being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis
Tebipenem HBr (tebipenem pivoxil hydrobromide) is an investigational oral carbapenem being developed for the treatment of cUTI, including pyelonephritis, to potentially help patients avoid hospitalizations and/or reduce the duration of in-patient therapy. If approved, Tebipenem is positioned to be the first oral carbapenem for this condition.
Spero Therapeutics and GSK announced in May 2025 that the PIVOT-PO Phase 3 trial evaluating tebipenem HBr has met its primary endpoint and will stop early for efficacy. Tebipenem HBr could potentially be the first oral carbapenem antibiotic for US patients with cUTIs including pyelonephritis.
For more details on this pivotal development, please see the full press release here.
Partnerships
Spero Therapeutics believes that forming collaborations with external partners is essential to maximizing the reach and impact of our innovative therapies for patients.
Investor Relations
Stock information, SEC filings, corporate governance, IR resources and more.
Careers
Join our life-changing mission to deliver differentiated treatments for those affected by rare and MDR bacterial infections. We seek individuals with unique talents who share our passion.
Spero Therapeutics and GSK announced that the PIVOT-PO Phase 3 trial for tebipenem HBr met its primary endpoint and will stop early for efficacy. Read the full press release here
